Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 28.05.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
For use Max Pidek Pharmaceuticals as monotherapy and in combination with clavulanic acid: an infectious-inflammatory diseases caused by susceptible microorganisms, including bronchitis, pneumonia, tonsillitis, pyelonephritis, urethritis, infections of the gastrointestinal tract, gynecological infections, infections of the skin and soft tissue, listeria, leptospirosis, gonorrhea.
For use Max Pidek Pharmaceuticals in combination with metronidazole: chronic gastritis in acute, peptic ulcer and duodenal ulcer in acute, associated with Helicobacter Pylori.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Seasonal Allergic Rhinitis
Levocetirizine (Alerfix TOTAL) dihydrochloride is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.
Perennial Allergic Rhinitis
Levocetirizine (Alerfix TOTAL) dihydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older.
Chronic Idiopathic Urticaria
Levocetirizine (Alerfix TOTAL) dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.It is indicated for: The prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age or older; the prevention of exercise-induced bronchoconstriction in patients 15 years of age and older; the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adult and pediatric patients 6 months of age and older).
Montelukast (Alerfix TOTAL) 4 mg: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is indicated in the treatment of asthma as add on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short-acting β-agonists provide inadequate clinical control of asthma.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is also indicated in the prophylaxis of asthma from 2 years of age to 5 years in which the predominant component is exercise-induced bronchoconstriction.
Montelukast (Alerfix TOTAL) 5 mg: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is indicated in the treatment of asthma as add on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short-acting β-agonists provide inadequate clinical control of asthma.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is also indicated in the prophylaxis of asthma in those 6 to 14 years old which the predominant component is exercise-induced bronchoconstriction.
Montelukast (Alerfix TOTAL) 10 mg: Montelukast (Alerfix TOTAL) sodium (Montelukast (Alerfix TOTAL)) is indicated in the treatment of asthma as add-on therapy in patients 15 years and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom "as-needed" short-acting β-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast (Alerfix TOTAL) sodium (Montelukast (Alerfix TOTAL)) is indicated in asthma, Montelukast (Alerfix TOTAL) sodium (Montelukast (Alerfix TOTAL)) can also provide symptomatic relief of seasonal allergic rhinitis.
Montelukast (Alerfix TOTAL) sodium (Montelukast (Alerfix TOTAL)) is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction in patients 15 years and older.
Relieving cough and throat and airway irritation due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.
Ambroxol (Alerfix TOTAL) is a cough suppressant and expectorant combination. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough. The expectorant works by loosening mucus and lung secretions in the chest and making coughs more productive.
Levocetirizine (Alerfix TOTAL) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Levocetirizine (Alerfix TOTAL) is used to treat symptoms of year-round (perennial) allergies in adults and children who are at least 6 months old. It is also used to treat symptoms of seasonal allergies in adults and children who are at least 2 years old.
Levocetirizine (Alerfix TOTAL) is also used to treat itching and swelling caused by chronic urticaria (hives) in adults and children who are at least 6 months old.
Levocetirizine (Alerfix TOTAL) may also be used for purposes not listed in this medication guide.
Montelukast (Alerfix TOTAL) is a leukotriene (loo-koe-TRY-een) inhibitor. Leukotrienes are chemicals your body releases when you breathe in an allergen (such as pollen). These chemicals cause swelling in your lungs and tightening of the muscles around your airways, which can result in asthma symptoms.
Montelukast (Alerfix TOTAL) is used to prevent asthma attacks in adults and children as young as 12 months old. Montelukast (Alerfix TOTAL) is also used to prevent exercise-induced bronchospasm in adults and children who are at least 6 years old.
Montelukast (Alerfix TOTAL) is also used to treat symptoms of year-round (perennial) allergies in adults and children who are at least 6 months old. It is also used to treat symptoms of seasonal allergies in adults and children who are at least 2 years old.
Do not give this medicine to a child without a doctor's advice.
Montelukast (Alerfix TOTAL) is also used to prevent exercise-induced bronchoconstriction (narrowing of the air passages in the lungs) in adults and teenagers who are at least 15 years old and are not already taking this medicine for other conditions.
If you already take Montelukast (Alerfix TOTAL) to prevent asthma or allergy symptoms, do not use an extra dose to treat exercise-induced bronchoconstriction.
Montelukast (Alerfix TOTAL) may also be used for purposes not listed in this medication guide.
Sustained-Release Capsule: Adults and Children >12 years: 1 cap once daily after meal with plenty of liquid (sufficient supply of liquid supports the expectorant effect of Ambroxol (Alerfix TOTAL)).
Ambroxol (Alerfix TOTAL) SR capsule is not suitable for children <12 years.
Tablet: Adults and Children >12 years: 1 tab thrice daily for the first 2-3 days and then 1 tab twice daily or ½ tab thrice daily. Children 6-12 years: ½ tab 2-3 times a day.
Syrup: Adults and Children >12 years: 10 mL thrice daily during the first 2-3 days, them 10 mL twice daily or 5 mL thrice daily. Children 6-12 years: 5 mL 2-3 times a day; 2-5 years: 2.5 mL 3 times a day; <2 years: 2.5 mL 2 times a day.
DS Syrup: Adults and Children >12 years: 5 mL thrice daily for 2-3 days then 5 mL twice daily for 2.5 mL thrice daily. Children 6-12 years: 2.5 mL 2-3 times a day.
Infant Drops: Children 13-24 months: 1.25 mL twice a day; 7-12 months: 1 mL twice a day; ≤6 months: 0.5 mL twice a day.
Levocetirizine (Alerfix TOTAL) is available as 2.5 mg/5 mL (0.5 mg/mL) oral solution and as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. Levocetirizine (Alerfix TOTAL) can be taken without regard to food consumption.
Adults And Children 12 Years Of Age and Older
The recommended dose of Levocetirizine (Alerfix TOTAL) is 5 mg (1 tablet or 2 teaspoons [10 mL] oral solution) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (½ tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening.
Children 6 To 11 Years Of Age
The recommended dose of Levocetirizine (Alerfix TOTAL) is 2.5 mg (½ tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults.
Children 6 Months To 5 Years Of Age
The recommended initial dose of Levocetirizine (Alerfix TOTAL) is 1.25 mg (½ teaspoon oral solution) [2.5mL] once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg.
Dose Adjustment For Renal And Hepatic Impairment
In adults and children 12 years of age and older with:
- Mild renal impairment (creatinine clearance [CLCR] = 50-80 mL/min): a dose of 2.5 mg once daily is recommended;
- Moderate renal impairment (CLCR = 30-50 mL/min): a dose of 2.5 mg once every other day is recommended;
- Severe renal impairment (CLCR = 10-30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3-4 days) is recommended;
- End-stage renal disease patients (CLCR < 10 mL/min) and patients undergoing hemodialysis should not receive Levocetirizine (Alerfix TOTAL).
No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.
How supplied
Dosage Forms And Strengths
Levocetirizine (Alerfix TOTAL) oral solution is a clear, colorless liquid containing 0.5 mg of Levocetirizine (Alerfix TOTAL) dihydrochloride per mL.
Levocetirizine (Alerfix TOTAL) tablets are white, film-coated, oval-shaped, scored, imprinted (with the letter Y in red color on both halves of the scored tablet) and contain 5 mg Levocetirizine (Alerfix TOTAL) dihydrochloride.
Storage And Handling
Levocetirizine (Alerfix TOTAL) tablets are white, film-coated, oval-shaped, scored, imprinted (with the letter Y in red color on both halves of the scored tablet) and contain 5 mg Levocetirizine (Alerfix TOTAL) dihydrochloride. They are supplied in unit of use HDPE bottles.
90 Tablets (NDC 50474-920-90)
Levocetirizine (Alerfix TOTAL) oral solution is a clear, colorless liquid containing 0.5 mg of Levocetirizine (Alerfix TOTAL) dihydrochloride per mL.
Oral Solution in 5 oz polypropylene bottles (
NDCStorage
Store at 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F).
Manufactured for: UCB, Inc., Smyrna, GA 30080. Revised: June 2016
Chewable Tablet 4-mg: Children 2 to 5 years: One 4 mg chewable tablet daily to be taken in the evening. Montelukast (Alerfix TOTAL) Chewable Tablet 4 mg should not be taken immediately with food. It should be taken at least 1 hour before or 2 hours after a meal.
Montelukast (Alerfix TOTAL) Chewable Tablets 4 mg are not recommended in children below 2 years of age.
Chewable Tablet 5-mg: Children 6 to 14 years: One 5 mg chewable tablet daily to be taken in the evening. Montelukast (Alerfix TOTAL) Chewable Tablet 5 mg should not be taken immediately with food. It should be taken at least 1 hour before or 2 hours after a meal.
Montelukast (Alerfix TOTAL) Chewable Tablets 5 mg are not recommended in children below 6 years of age.
Film-Coated Tablet 10-mg: Asthma or Asthma and Concomitant Seasonal Allergic Rhinitis: Adults and Adolescents ≥15 years: One 10-mg tablet daily to be taken in the evening.
Oral Granules:
Children 6 months to 5 years:Missed Dose: Resume the usual schedule of 1 tablet/sachet once daily. Do not give double dose to make up for a missed dose.
Administration: For oral use.
Chewable Tablets: It should be given to a child under adult supervision. It should be taken even when the child has no symptoms or if he/she has an acute asthma attack.
If the child is taking Montelukast (Alerfix TOTAL) Chewable Tablet, be sure that he/she does not take any other medicines that contain the same active ingredient, i.e. Montelukast (Alerfix TOTAL).
If the child takes more Montelukast (Alerfix TOTAL) Chewable Tablet than he/she should, contact the child’s physician immediately for advice.
Discontinuation of Treatment: Montelukast (Alerfix TOTAL) Chewable Tablet can treat the child’s asthma only if the child continues taking it. It is important for the child to continue taking Montelukast (Alerfix TOTAL) Chewable Tablet for as long as the physician prescribes. It will help control the child’s asthma.
Film-Coated Tablet 10-mg: The therapeutic effect of Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg on parameters of asthma control occurs within one day. Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg may be taken with or without food. Patients should be advised to continue taking Montelukast (Alerfix TOTAL) even if asthma is under control, as well as during periods of worsening asthma.
Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg should not be used concomitantly with other products containing the same active ingredient, Montelukast (Alerfix TOTAL).
No dosage adjustment is necessary for the elderly or for the patients with renal insufficiency or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.
Therapy with Montelukas Sandoz Film-Coated Tab 10 mg in relation to other treatment for asthma. It can be added to a patient's existing treatment regimen.
Inhaled Corticosteroids: Treatment with Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg can be used as add-on therapy in patients when inhaled corticosteroids plus "as needed" short-acting β-agonist provide inadequate clinical control. Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg should not be subtituted for inhaled corticosteriods.
Montelukast (Alerfix TOTAL) Film-Coated Tab 10 mg should not be used in children <15 years due to the high content of active substance.
Other dosage forms with appropriate strengths are available for young children.
Oral Granules:
Do not dissolve granules in water. However, the patient may take liquids after swallowing the granules.
See also:
What is the most important information I should know about Ambroxol (Alerfix TOTAL)?
Hypersensitivity to Ambroxol (Alerfix TOTAL) hydrochloride or to any other excipients of Ambroxol (Alerfix TOTAL).
In case of rare hereditary conditions that may be incompatible with an excipient of Ambroxol (Alerfix TOTAL), the use of Ambroxol (Alerfix TOTAL) is contraindicated.
See also:
What is the most important information I should know about Levocetirizine (Alerfix TOTAL)?
You should not use this medication if you are allergic to Levocetirizine (Alerfix TOTAL) or cetirizine (Zyrtec).
Do not take Levocetirizine (Alerfix TOTAL) if you have end-stage kidney disease or if you are on dialysis. Any child younger than 12 years old with kidney disease should not take Levocetirizine (Alerfix TOTAL).
Before taking Levocetirizine (Alerfix TOTAL), tell your doctor if you have liver disease, kidney disease, or gallbladder problems.
It is very important not to give a child more than the prescribed dose of this medication. A child's body absorbs twice as much of the same dose size of Levocetirizine (Alerfix TOTAL) as an adult's body.
Call your doctor if your symptoms do not improve, if they get worse, or if you also have a fever.
See also:
What is the most important information I should know about Montelukast (Alerfix TOTAL)?
Hypersensitivity to Montelukast (Alerfix TOTAL) sodium or to any of the excipients of Montelukast (Alerfix TOTAL).
Use in children: Montelukast (Alerfix TOTAL) should not be used in children <15 years due to high content of Montelukast (Alerfix TOTAL). Other dosage forms with appropriate strengths are available for younger children.
Use Ambroxol (Alerfix TOTAL) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Ambroxol (Alerfix TOTAL) by mouth with or without food.
- Drink plenty of water while taking Ambroxol (Alerfix TOTAL).
- If you miss a dose of Ambroxol (Alerfix TOTAL), take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Ambroxol (Alerfix TOTAL).
Use Levocetirizine (Alerfix TOTAL) solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Levocetirizine (Alerfix TOTAL) solution by mouth with or without food. Take it in the evening unless your doctor tells you otherwise.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you miss a dose of Levocetirizine (Alerfix TOTAL) solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Levocetirizine (Alerfix TOTAL) solution.
Use Montelukast (Alerfix TOTAL) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Montelukast (Alerfix TOTAL). Talk to your pharmacist if you have questions about this information.
- Take Montelukast (Alerfix TOTAL) by mouth with or without food.
- Do not open the packet until you are ready to use it.
- Montelukast (Alerfix TOTAL) may be placed directly in the mouth, dissolved in 1 teaspoonful (5 mL) of cold or room temperature baby formula or breast milk, or mixed with a spoonful of soft food at cold or room temperature before swallowing. Soft foods that may be used include applesauce, mashed carrots, rice, or ice cream. Be sure to swallow the entire spoonful right away (within 15 minutes). Do not store mixed medicine for future use.
- Do not put the granules in liquid other than baby formula or breast milk. However, you may drink liquids after swallowing the granules or granule mixture.
- Continue to use Montelukast (Alerfix TOTAL) even if you feel well. Do not miss any doses.
- If you miss a dose of Montelukast (Alerfix TOTAL), skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Montelukast (Alerfix TOTAL).
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Ambroxol (Alerfix TOTAL) is used to treat certain diseases of the respiratory tract and to relieve cough associated with thickened mucous.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Levocetirizine (Alerfix TOTAL) is used to treat symptoms of allergic conditions such as allergic fever (hay fever), year-round allergies like dust or pet allergies and chronic nettle rash.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled Indications
Allergic rhinitis (perennial or seasonal): Relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis
Asthma: Prophylaxis and chronic treatment of asthma
Bronchoconstriction, exercise-induced (prevention): Prevention of exercise-induced bronchoconstriction.
Note: American Academy of Otolaryngology, Head and Neck Surgery (AAO-HNS) and American Academy of Allergy, Asthma, and Immunology (AAAAI) and American College of Allergy, Asthma, and Immunology (ACAAI) guidelines recommend against Montelukast (Alerfix TOTAL) use as first-line therapy for allergic rhinitis (except in patients with concurrent asthma) (Dykewicz 2017; Seidman 2015). The Global Initiative for Asthma recommends Montelukast (Alerfix TOTAL) in patients with concomitant allergic rhinitis or those who cannot take inhaled corticosteroids (GINA 2019).
Off Label Uses
Chronic urticaria
Data from controlled, double-blind trials regarding the use of Montelukast (Alerfix TOTAL) in combination with antihistamines for the management of chronic urticaria are conflicting. Based on clinical practice guidelines from the American Academy of Allergy, Asthma and Immunology (AAAAI); the American College of Allergy, Asthma, and Immunology (ACAAI); the Joint Council of Allergy, Asthma and Immunology (JCAAI); and the World Allergy Organization for the diagnosis and management of acute and chronic urticaria, a leukotriene receptor antagonist may be added to antihistamine therapy in patients who do not respond to antihistamines. Access Full-Off Label Monograph
Urticaria (nonsteroidal anti-inflammatory drug-induced)
Data from a double-blind, placebo-controlled comparison of Montelukast (Alerfix TOTAL) and cetirizine in patients with chronic urticaria and intolerance to food additives and/or aspirin supports the use of Montelukast (Alerfix TOTAL) in the treatment of patients experiencing urticaria related to the use of nonsteroidal anti-inflammatory drugs.
See also:
What other drugs will affect Ambroxol (Alerfix TOTAL)?
Amoxicillin may decrease the effectiveness of contraceptives for oral administration.
With the simultaneous use of Max Pidek Pharmaceuticals with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin) appears synergies; with bacteriostatic antibiotic (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulphonamide) - antagonism.
Amoxicillin increases the effects of indirect anticoagulants inhibiting intestinal microflora, reduces the synthesis of vitamin K and prothrombin index.
Amoxicillin reduces the effect of drugs, in the process of metabolism that produce PABA.
Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs decrease the tubular secretion of amoxicillin, which can be accompanied by an increase in its concentration in blood plasma.
Antacids, glucosamine, laxatives, aminoglycosides, slow down and reduce, and ascorbic acid increases the absorption of amoxicillin.
With the combined use of amoxicillin and clavulanic acid pharmacokinetics of both components unchanged.
See also:
What other drugs will affect Levocetirizine (Alerfix TOTAL)?
Drug interaction studies have been performed with racemic cetirizine.
Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline and Pseudoephedrine: Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole and cimetidine. There was a small decrease (approximately 16%) in the clearance of cetirizine caused by theophylline 400 mg dose. It is possible that higher theophylline doses could have a greater effect. Interactions with Other Medicaments:
The extent of absorption of Levocetirizine (Alerfix TOTAL) is not reduced with food, although the rate of absorption is decreased.
In sensitive patients the simultaneous administration of cetirizine or Levocetirizine (Alerfix TOTAL) and alcohol or other CNS depressants, may have effects on the central nervous system, although it has been shown that the racemate cetirizine does not potentiate the effect of alcohol.
See also:
What other drugs will affect Montelukast (Alerfix TOTAL)?
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma, and in the treatment of allergic rhinitis. In drug-interactions studies, the recommended clinical dose of Montelukast (Alerfix TOTAL) did not have clinically important effects on the pharmacokinetics of the following drugs: Theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.
The area under the plasma concentration-time curve (AUC) for Montelukast (Alerfix TOTAL) was decreased approximately 40% in subjects with co-administration of phenobarbital. No dosage adjustment for Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is recommended.
In vitro studies have shown that Montelukast (Alerfix TOTAL) is an inhibitor of CYP2C8. However, data from a clinical drug-drug interaction study involving Montelukast (Alerfix TOTAL) and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that Montelukast (Alerfix TOTAL) does not inhibit CYP2C8 in vivo. Therefore, Montelukast (Alerfix TOTAL) is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g. paclitaxel, rosiglitazone, and repaglinide.)
In vitro studies have shown that Montelukast (Alerfix TOTAL) is a substrate of CYP 2C8, 2C9, and 3A4. Data from a clinical drug-drug interaction study involving Montelukast (Alerfix TOTAL) and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil increased the systemic exposure of Montelukast (Alerfix TOTAL) by 4.4-fold.
Co-administration of itraconazole, a strong CYP 3A4 inhibitor, with gemfibrozil and Montelukast (Alerfix TOTAL) did not further increase the systemic exposure of Montelukast (Alerfix TOTAL). The effect of gemfibrozil on systemic exposure of Montelukast (Alerfix TOTAL) is not considered to be clinically meaningful based on clinical safety data with doses greater than the 10 mg approved dose in adults (e.g., 200 mg/day to adult patients for 22 weeks, and up to 900 mg/day to patients for approximately one week) where clinically important adverse experiences were not observed. Therefore, no dosage adjustment of Montelukast (Alerfix TOTAL) is required upon co-administration with gemfibrozil. Based on in vitro data, clinically important drug interactions with other known inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. In addition, co-administration of Montelukast (Alerfix TOTAL) with itraconazole alone resulted in no significant increase in the systemic exposure of Montelukast (Alerfix TOTAL).
See also:
What are the possible side effects of Ambroxol (Alerfix TOTAL)?
Applies to albuterol: oral syrup, oral tablet, oral tablet extended release
Other dosage forms:
- inhalation aerosol powder, inhalation capsule, inhalation powder, inhalation solution
As well as its needed effects, albuterol (the active ingredient contained in Ambroxol (Alerfix TOTAL)) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking albuterol, check with your doctor immediately:
More common:
- Shakiness in the legs, arms, hands, or feet
- trembling or shaking of the hands or feet
- Fast, irregular, pounding, or racing heartbeat or pulse
- Cough
- difficulty breathing
- difficulty with swallowing
- hives or welts
- hoarseness
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- noisy breathing
- redness of the skin
- shortness of breath
- skin rash
- slow or irregular breathing
- swelling of the mouth or throat
- tightness in the chest
- wheezing
- Agitation
- anxiety
- arm, back, or jaw pain
- blurred vision
- chest pain or discomfort
- confusion
- convulsions
- extra heartbeats
- fainting
- hallucinations
- headache
- irritability
- lightheadedness
- mood or mental changes
- muscle pain or cramps
- muscle spasm or jerking of all extremities
- nervousness
- nightmares
- pounding in the ears
- restlessness
- sudden loss of consciousness
- sweating
- total body jerking
- unusual feeling of excitement
- vomiting
Minor Side Effects
Some albuterol side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Less common:
- Dizziness
- feeling of warmth
- irritability
- nausea
- redness of the face, neck, arms, and occasionally, upper chest
- sleeplessness
- trouble with holding or releasing urine
- trouble sleeping
- unable to sleep
- Sleepiness
- unusual drowsiness
- Bad, unusual, or unpleasant (after) taste
- change in taste
- feeling of constant movement of self or surroundings
- gagging
- rough, scratchy sound to voice
- sensation of spinning
- tightness in the throat
See also:
What are the possible side effects of Levocetirizine (Alerfix TOTAL)?
Use of Levocetirizine (Alerfix TOTAL) has been associated with somnolence, fatigue, asthenia, and urinary retention.
Clinical Trials Experience
The safety data described below reflect exposure to Levocetirizine (Alerfix TOTAL) in 2708 patients with seasonal or perennial allergic rhinitis or chronic idiopathic urticaria in 14 controlled clinical trials of 1 week to 6 months duration.
The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with Levocetirizine (Alerfix TOTAL) 2.5, 5, or 10 mg once daily in the evening.
The short-term safety data from pediatric patients are based upon two clinical trials in which 243 children with seasonal or perennial allergic rhinitis (162 males and 81 females 6 to 12 years of age) were treated with Levocetirizine (Alerfix TOTAL) 5 mg once daily for 4 to 6 weeks, one clinical trial in which 114 children (65 males and 49 females 1 to 5 years of age) with allergic rhinitis or chronic idiopathic urticaria were treated with Levocetirizine (Alerfix TOTAL) 1.25 mg twice daily for 2 weeks, and one clinical trial in which 45 children (28 males and 17 females 6 to 11 months of age) with symptoms of allergic rhinitis or chronic urticaria were treated with Levocetirizine (Alerfix TOTAL) 1.25 mg once daily for 2 weeks.
The long-term (exposure of 4 or 6 months) safety data in adults and adolescents are based upon two clinical trials in which 428 patients (190 males and 238 females) with allergic rhinitis were exposed to treatment with Levocetirizine (Alerfix TOTAL) 5 mg once daily. Long term safety data are also available from an 18-month trial in 255 Levocetirizine (Alerfix TOTAL)-treated subjects 12-24 months of age.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
Adults and Adolescents 12 years of Age and Older
In studies up to 6 weeks in duration, the mean age of the adult and adolescent patients was 32 years, 44% of the patients were men and 56% were women, and the large majority (more than 90%) was Caucasian.
In these trials 43% and 42% of the subjects in the Levocetirizine (Alerfix TOTAL) 2.5 mg and 5 mg groups, respectively, had at least one adverse event compared to 43% in the placebo group.
In placebo-controlled trials of 1-6 weeks in duration, the most common adverse reactions were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis, and most were mild to moderate in intensity. Somnolence with Levocetirizine (Alerfix TOTAL) showed dose ordering between tested doses of 2.5, 5 and 10 mg and was the most common adverse reaction leading to discontinuation (0.5%).
Table 1 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 12 years and older exposed to Levocetirizine (Alerfix TOTAL) 2.5 mg or 5 mg in eight placebo-controlled clinical trials and that were more common with Levocetirizine (Alerfix TOTAL) than placebo.
Table 1 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 12 Years and Older Exposed to Levocetirizine (Alerfix TOTAL) 2.5 mg or 5 mg Once Daily in Placebo-Controlled Clinical Trials 1-6 Weeks in Duration
Adverse Reactions | Levocetirizine (Alerfix TOTAL) 2.5 mg (n = 421) | Levocetirizine (Alerfix TOTAL) 5 mg (n = 1070) | Placebo (n = 912) |
Somnolence | 22 (5%) | 61 (6%) | 16 (2%) |
Nasopharyngitis | 25 (6%) | 40 (4%) | 28 (3%) |
Fatigue | 5 (1%) | 46 (4%) | 20 (2%) |
Dry Mouth | 12 (3%) | 26 (2%) | 11 (1%) |
Pharyngitis | 10 (2%) | 12 (1%) | 9 (1%) |
*Rounded to the closest unit percentage |
Additional adverse reactions of medical significance observed at a higher incidence than in placebo in adults and adolescents aged 12 years and older exposed to Levocetirizine (Alerfix TOTAL) are syncope (0.2%) and weight increased (0.5%).
Pediatric Patients 6 To 12 Years Of Age
A total of 243 pediatric patients 6 to 12 years of age received Levocetirizine (Alerfix TOTAL) 5 mg once daily in two short-term placebo controlled double-blind trials. The mean age of the patients was 9.8 years, 79 (32%) were 6 to 8 years of age, and 50% were Caucasian. Table 2 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 6 to 12 years exposed to Levocetirizine (Alerfix TOTAL) 5 mg in placebo-controlled clinical trials and that were more common with Levocetirizine (Alerfix TOTAL) than placebo.
Table 2 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 6-12 Years Exposed to Levocetirizine (Alerfix TOTAL) 5 mg Once Daily in Placebo-Controlled Clinical Trials 4 and 6 Weeks in Duration
Adverse Reactions | Levocetirizine (Alerfix TOTAL) 5 mg (n = 243) | Placebo (n = 240) |
Pyrexia | 10 (4%) | 5 (2%) |
Cough | 8 (3%) | 2 ( < 1%) |
Somnolence | 7 (3%) | 1 ( < 1%) |
Epistaxis | 6 (2%) | 1 ( < 1%) |
*Rounded to the closest unit percentage |
Pediatric Patients 1 To 5 Years Of Age
A total of 114 pediatric patients 1 to 5 years of age received Levocetirizine (Alerfix TOTAL) 1.25 mg twice daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 3.8 years, 32% were 1 to 2 years of age, 71% were Caucasian and 18% were Black. Table 3 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 1 to 5 years exposed to Levocetirizine (Alerfix TOTAL) 1.25 mg twice daily in the placebo-controlled safety trial and that were more common with Levocetirizine (Alerfix TOTAL) than placebo.
Table 3 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 1-5 Years Exposed to Levocetirizine (Alerfix TOTAL) 1.25 mg Twice Daily in a 2-Week Placebo-Controlled Clinical Trial
Adverse Reactions | Levocetirizine (Alerfix TOTAL) 1.25 mg Twice Daily (n = 114) | Placebo (n = 59) |
Pyrexia | 5 (4%) | 1 (2%) |
Diarrhea | 4 (4%) | 2 (3%) |
Vomiting | 4 (4%) | 2 (3%) |
Otitis Media | 3 (3%) | 0 (0%) |
*Rounded to the closest unit percentage |
Pediatric Patients 6 To 11 Months Of Age
A total of 45 pediatric patients 6 to 11 months of age received Levocetirizine (Alerfix TOTAL) 1.25 mg once daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse reactions that were reported in more than 1 subject (i.e. greater than or equal to 3% of subjects) aged 6 to 11 months exposed to Levocetirizine (Alerfix TOTAL) 1.25 mg once daily in the placebo-controlled safety trial and that were more common with Levocetirizine (Alerfix TOTAL) than placebo included diarrhea and constipation which were reported in 6 (13%) and 1 (4%) and 3 (7%) and 1 (4%) children in the Levocetirizine (Alerfix TOTAL) and placebo-treated groups, respectively.
Long-Term Clinical Trials Experience
In two controlled clinical trials, 428 patients (190 males and 238 females) aged 12 years and older were treated with Levocetirizine (Alerfix TOTAL) 5 mg once daily for 4 or 6 months. The patient characteristics and the safety profile were similar to that seen in the short-term studies. Ten (2.3%) patients treated with Levocetirizine (Alerfix TOTAL) discontinued because of somnolence, fatigue or asthenia compared to 2 ( < 1%) in the placebo group.
There are no long term clinical trials in children below 12 years of age with allergic rhinitis or chronic idiopathic urticaria.
Laboratory Test Abnormalities
Elevations of blood bilirubin and transaminases were reported in < 1% of patients in the clinical trials. The elevations were transient and did not lead to discontinuation in any patient.
Post-Marketing Experience
In addition to the adverse reactions reported during clinical trials and listed above, adverse reactions have also been identified during post-approval use of Levocetirizine (Alerfix TOTAL). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions of hypersensitivity and anaphylaxis, increased appetite, angioedema, fixed drug eruption, pruritus, rash and urticaria, convulsion, paraesthesia, dizziness, tremor, dysgeusia, vertigo, movement disorders (including dystonia and oculogyric crisis), aggression and agitation, hallucinations, depression, insomnia, suicidal ideation, visual disturbances, blurred vision, palpitations, tachycardia, dyspnea, nausea, vomiting, hepatitis, dysuria, urinary retention, myalgia, arthralgia, and edema have been reported.
Besides these reactions reported under treatment with Levocetirizine (Alerfix TOTAL), other potentially severe adverse events have been reported from the post-marketing experience with cetirizine. Since Levocetirizine (Alerfix TOTAL) is the principal pharmacologically active component of cetirizine, one should take into account the fact that the following adverse events could also potentially occur under treatment with Levocetirizine (Alerfix TOTAL): orofacial dyskinesia, severe hypotension, cholestasis, glomerulonephritis, still birth, tic, myoclonus, and extrapyramidal symptoms.
See also:
What are the possible side effects of Montelukast (Alerfix TOTAL)?
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been generally well tolerated. Side effects, which usually were mild, generally did not require discontinuation of therapy. The overall incidence of side effects reported with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) was comparable to placebo.
Adults 15 Years of Age and Older with Asthma: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in approximately 2600 adult patients 15 years of age and older in clinical studies. In two similarly designed, 12-week placebo-controlled clinical studies, the only adverse experiences reported as drug related in ≥ 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo were abdominal pain and headache. The incidences of these events were not significantly different in the two treatment groups.
Cumulatively, 544 patients were treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) for at least 6 months, 253 for one year and 21 for 2 years in clinical studies. With prolonged treatment, the adverse experience profile did not change.
Pediatric Patients 6 to 14 Years of Age with Asthma: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in approximately 475 pediatric patients 6 to 14 years of age. The safety profile in pediatric patients is generally similar to the adult safety profile and to placebo.
In an 8-week, placebo-controlled clinical study, the only adverse experience reported as drug related in > 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo was headache. The incidence of headache was not significantly different in the two treatment groups.
In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)).
Cumulatively, 263 pediatric patients 6 to 14 years of age were treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) for at least 3 months and 164 for 6 months or longer. With prolonged treatment, the adverse experience profile did not change.
Pediatric Patients 2 to 5 Years of Age with Asthma: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in 573 pediatric patients 2 to 5 years of age. In a 12-week, placebo-controlled clinical study, the only adverse experience reported as drug related in > 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo was thirst. The incidence of thirst was not significantly different in the two treatment groups.
Cumulatively, 426 pediatric patients 2 to 5 years of age were treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) for at least 3 months, 230 for 6 months or longer, and 63 patients for 12 months or longer. With prolonged treatment, the adverse experience profile did not change.
Pediatric Patients 6 Months to 2 Years of Age with Asthma: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in 175 pediatric patients 6 months to 2 years of age. In a 6-week, placebo-controlled clinical study, the adverse experiences reported as drug related in > 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo were diarrhea, hyperkinesia, asthma, eczematous dermatitis and rash.
The incidences of these adverse experiences were not significantly different in the two treatment groups.
Adults 15 Years of Age and Older with Seasonal Allergic Rhinitis: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in 2199 adult patients 15 years of age and older for the treatment of seasonal allergic rhinitis in clinical studies. Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) administered once daily in the morning or in the evening was generally well tolerated with a safety profile similar to that of placebo. In placebo-controlled clinical studies, no adverse experiences reported as drug related in 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo were observed. In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies. The incidence of somnolence was similar to that of placebo in all studies.
Pediatric Patients 2 to 14 Years of Age with Seasonal Allergic Rhinitis: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in 280 pediatric patients 2 to 14 years of age for the treatment of seasonal allergic rhinitis in a 2-week, placebo-controlled, clinical study. Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) administered once daily in the evening was generally well tolerated with a safety profile similar to that of placebo. In this study, no adverse experiences reported as drug related in 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo were observed.
Adults 15 Years of Age and Older with Perennial Allergic Rhinitis: Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) has been evaluated in 3235 adult and adolescent patients 15 years of age and older with perennial allergic rhinitis in two, 6-week, placebo-controlled, clinical studies.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) administered once daily was generally well tolerated, with a safety profile consistent with that observed in patients with seasonal allergic rhinitis and similar to that of placebo. In these two studies, no adverse experiences reported as drug related in 1% of patients treated with Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and at a greater incidence than in patients treated with placebo were observed. The incidence of somnolence was similar to that of placebo.
Pooled Analyses of Clinical Trials Experience: A pooled analysis of 41 placebo-controlled clinical studies (35 studies in patients 15 years of age and older; 6 studies in pediatric patients 6 to 14 years of age) was performed using a validated assessment method of suicidality. Among the 9929 patients who received Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and 7780 patients who received placebo in these studies, there was one patient with suicidal ideation in the group taking Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)). There were no completed suicides, suicide attempts or preparatory acts toward suicidal behavior in either treatment group.
A separate pooled analysis of 46 placebo-controlled clinical studies (35 studies in patients 15 years of age and older; 11 studies in pediatric patients 3 months to 14 years of age) assessing behavior-related adverse experiences (BRAEs) was performed. Among the 11,673 patients who received Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and 8827 patients who received placebo in these studies, the frequency of patients with at least one BRAE was 2.73% in patients who received Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) and 2.27% in patients who received placebo; the odds ratio was 1.12 [95% CI (0.93; 1.36)].
The clinical trials included in these pooled analyses were not designed specifically to examine suicidality or BRAEs.
Postmarketing Experience: The following side effects have been reported in postmarketing use: Infections and Infestations: Upper respiratory infection.
Blood and Lymphatic System Disorders: Increased bleeding tendency.
Immune System Disorders: Hypersensitivity reactions including anaphylaxis, very rarely hepatic eosinophilic infiltration.
Psychiatric Disorders: Agitation including aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, hallucinations, insomnia, memory impairment, psychomotor hyperactivity (including irritability, restlessness, and tremor) somnambulism, suicidal thinking and behavior (suicidality).
Nervous System Disorders: Dizziness, drowsiness, paraesthesia/hypoesthesia, very rarely seizure.
Cardiac Disorders: Palpitations.
Respiratory, Thoracic and Mediastinal Disorders: Epistaxis.
Gastrointestinal Disorders: Diarrhea, dyspepsia, nausea, vomiting; pulmonary eosinophilia.
Hepatobiliary Disorders: Increased ALT and AST, very rarely hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).
Skin and Subcutaneous Tissue Disorders: Angioedema, bruising, erythema multiforme, erythema nodosum, pruritus, rash, urticaria.
Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia including muscle cramps.
Renal and Urinary Disorders: Enuresis in children.
General Disorders and Administration Site Conditions: Asthenia/fatigue, edema, pyrexia.
Each retard capsule contains Ambroxol (Alerfix TOTAL) hydrochloride 75 mg.
Each tablet contains Ambroxol (Alerfix TOTAL) hydrochloride 30 mg.
Each 5 mL of syrup contains Ambroxol (Alerfix TOTAL) hydrochloride 15 or 30 mg.
Each mL of syrup (infant drops) contains Ambroxol (Alerfix TOTAL) hydrochloride 6 mg.
Ambroxol (Alerfix TOTAL) hydrochloride is trans-4-[(2-amino-3,5-dibromo-benzyl)amino] cyclohexanol hydrochloride.
It also contains the following excipients: Retard Capsules: Crospovidone collidon CL, carnauba wax, stearyl alcohol, magnesium stearate.
Tablets: Lactose, maize starch, colloidal silica, magnesium stearate.
Syrup: Purified water, sorbitol liquid, glycerol 85%, woodberry aroma (15 mg only), strawberry aroma (30 mg only), hydroxyethylcellulose, benzoic acid, acesulfame potassium, vanilla aroma.
Infant Drops: Hydroxyethylcellulose, sorbitol solution, glycerol 85%, sodium saccharin, pharma flavors, menthol, benzoic acid, propylene glycol.
Levocetirizine (Alerfix TOTAL) is a third-generation non-sedative antihistamine indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It was developed from the second-generation antihistamine cetirizine. Levocetirizine (Alerfix TOTAL) is the R-enantiomer of the cetirizine racemate. Levocetirizine (Alerfix TOTAL) is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells. Levocetirizine (Alerfix TOTAL) was approved by the United States Food and Drug Administration on May 25, 2007 and is marketed under the brand Levocetirizine (Alerfix TOTAL)® by sanofi-aventis U.S. LLC.
Each 10-mg film-coated tablet contains 10.4 mg Montelukast (Alerfix TOTAL) sodium, which is the molar equivalent to 10.0 mg of free acid. Each 5-mg chewable tablet contains 5.2 mg Montelukast (Alerfix TOTAL) sodium, which is the molar equivalent to 5.0 mg of free acid. Each 4-mg chewable tablet and each packet of 4-mg oral granules contains 4.2 mg Montelukast (Alerfix TOTAL) sodium, which is the molar equivalent to 4.0 mg of free acid.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is a selective and orally active leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene CysLT1 receptor.
Montelukast (Alerfix TOTAL) (Montelukast (Alerfix TOTAL)) is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid, monosodium salt.
The empirical formula is C35H35ClNNaO3S, and its molecular weight is 608.18.
Montelukast (Alerfix TOTAL) sodium is a hygroscopic, optically active, white to off-white powder. Montelukast (Alerfix TOTAL) sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile.